共查询到20条相似文献,搜索用时 31 毫秒
1.
James B Whitney Saied Mirshahidi So-Yon Lim Lauren Goins Chris C Ibegbu Daniel C Anderson Richard B Raybourne Fred R Frankel Judy Lieberman Ruth M Ruprecht 《Journal of immune based therapies and vaccines》2011,9(1):2
Background
We have evaluated an attenuated Listeria monocytogenes (Lm) candidate vaccine vector in nonhuman primates using a delivery regimen relying solely on oral vaccination. We sought to determine the impact of prior Lm vector exposure on the development of new immune responses against HIV antigens. 相似文献2.
Rajpal S Kashyap Aliabbas A Husain Shweta H Morey Milind S Panchbhai Poonam S Deshpande Hemant J Purohit Girdhar M Taori Hatim F Daginawala 《Journal of immune based therapies and vaccines》2010,8(1):3
Background
Tuberculosis (TB) is one of the most prevalent cause of death due to a single pathogen. Bacillus Calmette Guérin (BCG) is the only vaccine available for clinical use that protects against miliary TB; however, this vaccine has shown variable levels of efficacy against pulmonary TB. In India, a single dose of BCG vaccine is given and there are few countries where repeated doses of BCG are given. The incidence of TB in India is very high inspite of primary vaccination in neonatal period and therefore requires consideration for repeated immunization. 相似文献3.
Vladimir Liska Stacey A Bigert Philip S Bennett David Olsen Robert Chang Carl J Burke 《Journal of immune based therapies and vaccines》2007,5(1):4-6
Background
The labile nature of live, attenuated varicella-zoster virus (Oka/Merck) requires robust stabilization during virus bulk preparation and vaccine manufacturing in order to preserve potency through storage and administration. One stabilizing ingredient used in a varicella-zoster virus (VZV) vaccine is hydrolyzed porcine gelatin which represents the major protein/peptide-based excipient in the vaccine formulation. 相似文献4.
Background
Hemodialysis patient are at high risk for hepatitis B virus (HBV) infection. 相似文献5.
Harm HogenEsch Anisa Dunham Bethany Hansen Kathleen Anderson Jean-Francois Maisonneuve Stanley L Hem 《Journal of immune based therapies and vaccines》2011,9(1):1-10
Background
Streptococcus pneumoniae causes widespread morbidity and mortality. Current vaccines contain free polysaccharides or protein-polysaccharide conjugates, and do not induce protection against serotypes that are not included in the vaccines. An affordable and broadly protective vaccine is very desirable. The goal of this study was to determine the optimal formulation of a killed whole cell pneumococcal vaccine with aluminum-containing adjuvants for intramuscular injection.Methods
Four aluminium-containing adjuvants were prepared with different levels of surface phosphate groups resulting in different adsorptive capacities and affinities for the vaccine antigens. Mice were immunized three times and the antigen-specific antibody titers and IL-17 responses in blood were analyzed.Results
Although all adjuvants induced significantly higher antibody titers than antigen without adjuvant, the vaccine containing aluminum phosphate adjuvant (AP) produced the highest antibody response when low doses of antigen were used. Aluminum hydroxide adjuvant (AH) induced an equal or better antibody response at high doses compared with AP. Vaccines formulated with AH, but not with AP, induced an IL-17 response. The vaccine formulated with AH was stable and retained full immunogenicity when stored at 4°C for 4 months.Conclusions
Antibodies are important for protection against systemic streptococcal disease and IL-17 is critical in the prevention of nasopharyngeal colonization by S. pneumoniae in the mouse model. The formulation of the whole killed bacterial cells with AH resulted in a stable vaccine that induced both antibodies and an IL-17 response. These experiments underscore the importance of formulation studies with aluminium containing adjuvants for the development of stable and effective vaccines. 相似文献6.
Nelson F Eng Srinivas Garlapati Volker Gerdts Lorne A Babiuk George K Mutwiri 《Journal of immune based therapies and vaccines》2010,8(1):4
Background
We previously demonstrated that polyphosphazenes, particularly PCEP, enhance immune responses in mice immunized subcutaneously and intranasally. The objective of the present study was to investigate the efficacy of polyphosphazenes as adjuvants when delivered through different routes of vaccine administration. 相似文献7.
Chrystelle Brignone Caroline Grygar Manon Marcu Gaëlle Perrin Frédéric Triebel 《Journal of immune based therapies and vaccines》2007,5(1):5-15
Background
LAG-3 (CD223) is a natural high affinity ligand for MHC class II. The soluble form (sLAG-3) induces maturation of monocyte-derived dendritic cells in vitro and is used as a potent Th1-like immune enhancer with many antigens in animal models. To extend this observation to human, a proof of concept study was conducted with a clinical-grade sLAG-3, termed IMP321, coinjected with alum-non-absorbed recombinant hepatitis B surface antigen. 相似文献8.
Jerome S Harms Marina A Durward Diogo M Magnani Gary A Splitter 《Journal of immune based therapies and vaccines》2009,7(1):1-14
Background
There is no safe, effective human vaccine against brucellosis. Live attenuated Brucella strains are widely used to vaccinate animals. However these live Brucella vaccines can cause disease and are unsafe for humans. Killed Brucella or subunit vaccines are not effective in eliciting long term protection. In this study, we evaluate an approach using a live, non-pathogenic bacteria (E. coli) genetically engineered to mimic the brucellae pathway of infection and present antigens for an appropriate cytolitic T cell response. 相似文献9.
Curtis L Cooper Navneet K Ahluwalia Susan M Efler Jörg Vollmer Arthur M Krieg Heather L Davis 《Journal of immune based therapies and vaccines》2008,6(1):3
Background
Chronic hepatitis C virus (HCV) infection results from weak or absent T cell responses. Pegylated-interferon-alpha (IFN-α) and ribavirin, the standard of care for chronic HCV, have numerous immune effects but are not potent T cell activators. A potent immune activator such as TLR9 agonist CpG oligodeoxynucleotide (CpG) may complement current treatment approaches. 相似文献10.
So-Yon Lim Adam Bauermeister Richard A Kjonaas Swapan K Ghosh 《Journal of immune based therapies and vaccines》2006,4(1):5-10
Background
Adjuvants are known to significantly enhance vaccine efficacy. However, commercial adjuvants often have limited use because of toxicity in humans. The objective of this study was to determine the comparative effectiveness of a diterpene alcohol, phyto l and its hydrogenated derivative PHIS-01, relative to incomplete Freund's adjuvant (IFA), a commonly used adjuvant in augmenting protective immunity in mice against E. coli and S. aureus, and in terms of inflammatory cytokines. 相似文献11.
B Anuradha CM Santosh V Hari Sai Priya G Suman Latha KJR Murthy Valluri Vijaya Lakshmi 《Journal of immune based therapies and vaccines》2007,5(1):8-7
Background
Mycobacterium bovis BCG vaccine has displayed inconsistent efficacy in different trials conducted in various geographical regions. Nevertheless, it significantly reduces the risk of severe childhood tuberculosis and continues to be used to prevent tuberculosis in many countries. Many studies revealed that efficacy of vaccine wanes with age. Most of the studies were based on in vivo and in vitro responses to tuberculin. With the advent of newer tests such as in vitro interferon-γ assays and identification of potent immunogenic mycobacterial proteins there is a need to corroborate the observations. This study aims at ascertaining the need for a booster at a later age as indicated by in vitro release of IFN-γ while evaluating Ag85A as an antigen. 相似文献12.
Garry L Morefield Ralph F Tammariello Bret K Purcell Patricia L Worsham Jennifer Chapman Leonard A Smith Jason B Alarcon John A Mikszta Robert G Ulrich 《Journal of immune based therapies and vaccines》2008,6(1):5
Background
Combination vaccines reduce the total number of injections required for each component administered separately and generally provide the same level of disease protection. Yet, physical, chemical, and biological interactions between vaccine components are often detrimental to vaccine safety or efficacy. 相似文献13.
Wen Ji Yuan Takao Yasuhara Tetsuro Shingo Kenichiro Muraoka Takashi Agari Masahiro Kameda Takashi Uozumi Naoki Tajiri Takamasa Morimoto Meng Jing Tanefumi Baba Feifei Wang Hanbai Leung Toshihiro Matsui Yasuyuki Miyoshi Isao Date 《BMC neuroscience》2008,9(1):1-11
Background
A recent human clinical trial of an Alzheimer's disease (AD) vaccine using amyloid beta (Aβ) 1–42 plus QS-21 adjuvant produced some positive results, but was halted due to meningoencephalitis in some participants. The development of a vaccine with mutant Aβ peptides that avoids the use of an adjuvant may result in an effective and safer human vaccine.Results
All peptides tested showed high antibody responses, were long-lasting, and demonstrated good memory response. Epitope mapping indicated that peptide mutation did not lead to epitope switching. Mutant peptides induced different inflammation responses as evidenced by cytokine profiles. Ig isotyping indicated that adjuvant-free vaccination with peptides drove an adequate Th2 response. All anti-sera from vaccinated mice cross-reacted with human Aβ in APP/PS1 transgenic mouse brain tissue.Conclusion
Our study demonstrated that an adjuvant-free vaccine with different Aβ peptides can be an effective and safe vaccination approach against AD. This study represents the first report of adjuvant-free vaccines utilizing Aβ peptides carrying diverse mutations in the T-cell epitope. These largely positive results provide encouragement for the future of the development of human vaccinations for AD. 相似文献14.
Malley R Stack AM Husson RN Thompson CM Fleisher GR Saladino RA 《Journal of immune based therapies and vaccines》2004,2(1):2
Background
A recently licensed pneumococcal conjugate vaccine has been shown to be highly effective in the prevention of bacteremia in immunized children but the degree of protection against pneumonia has been difficult to determine. 相似文献15.
Qian-Quan Sun 《BMC neuroscience》2009,10(1):131-21
Background
Little is known about the roles of dendritic gap junctions (GJs) of inhibitory interneurons in modulating temporal properties of sensory induced responses in sensory cortices. Electrophysiological dual patch-clamp recording and computational simulation methods were used in combination to examine a novel role of GJs in sensory mediated feed-forward inhibitory responses in barrel cortex layer IV and its underlying mechanisms. 相似文献16.
Rubens R Santos Jr Alexandrina Sartori Deison S Lima Patrícia RM Souza Arlete AM Coelho-Castelo Vania LD Bonato Célio L Silva 《Journal of immune based therapies and vaccines》2009,7(1):4-12
Background
Our group previously demonstrated that a DNA plasmid encoding the mycobacterial 65-kDa heat shock protein (DNA-HSP65) displayed prophylactic and therapeutic effect in a mice model for tuberculosis. This protection was attributed to induction of a strong cellular immunity against HSP65. As specific immunity to HSP60 family has been detected in arthritis, multiple sclerosis and diabetes, the vaccination procedure with DNA-HSP65 could induce a cross-reactive immune response that could trigger or worsen these autoimmune diseases. 相似文献17.
Johann Steiner Hans-Gert Bernstein Hendrik Bielau Annika Berndt Ralf Brisch Christian Mawrin Gerburg Keilhoff Bernhard Bogerts 《BMC neuroscience》2007,8(1):2
Background
S100B is considered an astrocytic in-situ marker and protein levels in cerebrospinal fluid (CSF) or serum are often used as biomarker for astrocytic damage or dysfunction. However, studies on S100B in the human brain are rare. Thus, the distribution of S100B was studied by immunohistochemistry in adult human brains to evaluate its cell-type specificity. 相似文献18.
Sawada-Hirai R Jiang I Wang F Sun SM Nedellec R Ruther P Alvarez A Millis D Morrow PR Kang AS 《Journal of immune based therapies and vaccines》2004,2(1):5
Background
Potent anthrax toxin neutralizing human monoclonal antibodies were generated from peripheral blood lymphocytes obtained from Anthrax Vaccine Adsorbed (AVA) immune donors. The anti-anthrax toxin human monoclonal antibodies were evaluated for neutralization of anthrax lethal toxin in vivo in the Fisher 344 rat bolus toxin challenge model. 相似文献19.
Background
The gram-positive bacterium Streptococcus pyogenes is a common pathogen of humans that causes invasive infections, toxic-shock syndrome, rheumatic fever, necrotizing fasciitis and other diseases. Detection of antibiotic resistance in clinical isolates has renewed interest in development of new vaccine approaches for control S. pyogenes sepsis. In the study presented, a novel protein vaccine was examined. The vaccine was based on a recombinant protein fusion between streptococcal pyrogenic exotoxin B (SpeB), a cysteinyl protease expressed by all clinical isolates, and streptococcal pyrogenic exotoxin A (SpeA), a superantigen produced by a large subset of isolates.Results
A novel protein was produced by mutating the catalytic site of SpeB and the receptor binding surface of SpeA in a fusion of the two polypeptides. Vaccination of HLA-DQ8 transgenic mice with the SpeA-SpeB fusion protein protected against a challenge with the wild-type SpeA that was lethal to naïve controls, and vaccinated mice were protected from an otherwise lethal S. pyogenes infection.Conclusion
These results suggest that the genetically attenuated SpeA-SpeB fusion protein may be useful for controlling S. pyogenes infections. Vaccination with the SpeA-SpeB fusion protein described in this study may potentially result in protective immunity against multiple isolates of S. pyogenes due to the extensive antibody cross-reactivity previously observed among all sequence variants of SpeB and the high frequency of SpeA-producing strains. 相似文献20.